Bruker Bets on Fusion Energy Supply Chain as Wall Street Stays on the Sidelines

On September 4, Bruker (NASDAQ: BRKR) announced that its energy and superconductor technologies unit, Bruker Energy & Supercon Technologies (BEST), had entered a supply collaboration with Luvata Materials & Solutions to scale up production of RRP superconductors for magnetic confinement fusion. The agreement arrives as governments and private developers from Europe to South Korea race to build fusion demonstration plants, and it follows, by roughly a month, the first tangible signs of stabilization in Bruker's core scientific instruments business. Two very different narratives are converging inside a single stock.

A Front Row Seat to Fusion

The Luvata partnership is not Bruker's first venture in fusion. BEST and Luvata previously supplied materials and expertise to ITER, the international fusion megaproject, and to the Wendelstein 7-X stellarator — two of the most advanced superconducting plasma facilities ever built. Their RRP superconductors, wires manufactured with the Rod-Restack Process to withstand field strengths of 12 to 20 Tesla, already operate inside CERN's Large Hadron Collider and in ultra-high field NMR magnets. That track record is relevant now because fusion programs are ramping up across Europe, the Americas, China, Japan and South Korea, and Gauss Fusion has already begun evaluating RRP superconductors for its Gauss Industrial Demonstrator and GIGA power plant platform.

The interest in suppliers like Bruker reflects a broader shift in the fusion sector. Magnetic confinement approaches such as tokamaks and stellarators depend on high-field superconducting magnets, which has made specialized wire and cable producers a chokepoint as demonstration projects multiply. For companies that already manufacture these conductors at scale, fusion programs represent a potential new demand channel layered on top of existing scientific and medical markets — one reason supply-chain positioning has drawn increasing attention as the field moves from experiments toward prototype power plants.

The segment is already producing results. On August 4, Bruker reported that BEST revenue climbed 11.9% year over year to $74.2 million in the second quarter, with organic growth of 8.9% net of intercompany eliminations, while first-half BEST revenue rose 12.3% to $141 million. That growth also reached the bottom line. Non-GAAP operating margin expanded to 14.1% from 9% a year earlier, and non-GAAP diluted earnings per share grew to $0.49 from $0.32 — results strong enough that management maintained its full-year non-GAAP EPS growth target of 15% to 17%.

Fusion's Payoff Is Still Theoretical

None of that strength appears on a GAAP basis. Bruker's second-quarter GAAP operating results swung to a $65.3 million loss, versus GAAP operating income of $11.9 million a year earlier, dragged down largely by a $134.9 million non-cash goodwill charge. GAAP diluted earnings per share swung to a loss of $0.41 from a profit of $0.05, and for the first half of 2026 the company posted a GAAP diluted loss per share of $0.39. Impairments do not consume cash, but they are a reminder that some of what Bruker paid for in past acquisitions is now being written down.

The core business has not fully turned the corner either. Total second-quarter revenue grew only 2.8% organically, or 3.4% excluding tariff refunds, and first-half organic revenue actually declined 0.8% year over year. CEO Frank Laukien acknowledged that US academic demand remained soft during the quarter, even as bookings in Europe and China picked up. That softness matters because scientific instruments remain the overwhelming majority of Bruker's revenue, so even strong BEST growth cannot by itself offset sluggish instrument demand in the near term.

Fusion, meanwhile, remains a small part of the business. BEST's $74.2 million in quarterly revenue is less than 9% of total company revenue, and the Luvata agreement itself came with no disclosed contract value, order volume or timeline — meaning investors are being asked to price in a growth story that has not yet produced a number.

Wall Street Isn't Fully Convinced

Hedge fund ownership of Bruker rose from 34 funds to 45 funds quarter over quarter, a pattern consistent with institutional money adding to positions rather than trimming them. Short interest, however, sits at 14.91% of float, a level indicating that a real and sizable bear camp remains positioned against the stock. Shares traded at a forward price-to-earnings ratio of 15.22 as of September 4, a modest multiple that does not appear to price in much fusion-driven upside. Together, those signals suggest the market is still waiting for proof before committing either way.

The Bet Investors Are Weighing

Bruker is effectively trying to be two companies at once: a legacy scientific instruments maker navigating a soft academic market, and an early mover in what could become a critical fusion energy supply chain. The Luvata collaboration adds credibility to the second story by putting Bruker's superconductors in front of projects such as Gauss Fusion's demonstrator, but it does not yet carry a dollar figure. The first story is showing tangible progress, with BEST revenue growing at a double-digit rate and margins widening, even as GAAP results were weighed down by a one-time impairment charge. What would make the fusion narrative measurable — disclosed contract values, order volumes or timelines from the Luvata collaboration, or new commercial awards from named demonstration projects — is exactly what the announcement left out. Until those numbers surface, the market's wait-and-see stance has a factual basis.